

# Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

## NCI-H1975 EGFR-T790M/C797S/L858R

RRID:CVCL\_UE30

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_UE30

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_UE30](https://web.expasy.org/cellosaurus/CVCL_UE30)

**Proper Citation:** RRID:CVCL\_UE30

**Description:** Cell line NCI-H1975 EGFR-T790M/C797S/L858R is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Lung adenocarcinoma

**Comments:** Population: Caucasian.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NCI-H1975 EGFR-T790M/C797S/L858R

**Synonyms:** NCI-H1975 L858R/T790M/C797S

**Cross References:** cancercellines:CVCL\_UE30, KYinno:KC-0128, Wikidata:Q95993283

**ID:** CVCL\_UE30

**Hierarchy:** cvcl\_1511

**Record Creation Time:** 20220427T220838+0000

**Record Last Update:** 20260829T234731+0000

---

### Ratings and Alerts

No rating or validation information has been found for NCI-H1975 EGFR-T790M/C797S/L858R.

No alerts have been found for NCI-H1975 EGFR-T790M/C797S/L858R.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. *Molecular cancer therapeutics*, 25(1), 84.

Han J, et al. (2025) The Glycosyltransferase XYLT1 Activates NF- $\kappa$ B Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma. *Cancer research*, 85(9), 1628.

Shia CS, et al. (2025) Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. *Molecular cancer therapeutics*, 24(12), 1938.

Sealover NE, et al. (2024) In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies. *iScience*, 27(1), 108711.

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(3), 506.

Xiao P, et al. (2021) Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner. *Molecular cancer research : MCR*, 19(4), 726.

Vemulapalli V, et al. (2021) Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. *eLife*, 10.

Theard PL, et al. (2020) Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer. *eLife*, 9.